Richman, Douglas D.
Douglas Richman American virologist
Richman, Douglas D., 1943-...., professeur de pathologie et de médecine
Richman, Douglas D., 1943-
VIAF ID: 65748137 (Personal)
Permalink: http://viaf.org/viaf/65748137
Preferred Forms
-
100 0 _ ‡a Douglas Richman ‡c American virologist
-
-
-
-
100 1 _ ‡a Richman, Douglas D.
-
100 1 _ ‡a Richman, Douglas D.
-
-
100 1 _ ‡a Richman, Douglas D.
-
-
-
100 1 _ ‡a Richman, Douglas D.
-
-
-
100 1 _ ‡a Richman, Douglas D.
-
-
100 1 _ ‡a Richman, Douglas D., ‡d 1943-...., ‡c professeur de pathologie et de médecine
4xx's: Alternate Name Forms (7)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Absence of detectable HIV-1 viremia after treatment cessation in an infant |
![]() |
Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement |
![]() |
Antiviral Drug Discovery To Address the COVID-19 Pandemic |
![]() |
Antiviral drug resistance |
![]() ![]() ![]() ![]() |
Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size |
![]() |
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs |
![]() |
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals |
![]() |
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient |
![]() |
Clinical virology |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies |
![]() |
Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. |
![]() |
Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals |
![]() |
Encyclopedia of AIDS |
![]() |
Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types |
![]() |
Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. |
![]() |
The Future of HIV-1 Therapeutics : Resistance Is Futile? |
![]() ![]() ![]() |
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. |
![]() |
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment |
![]() |
HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat |
![]() |
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. |
![]() |
HIV-associated neurocognitive disorder is associated with HIV-1 dual infection |
![]() |
HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor |
![]() |
HIV type 1 |
![]() |
HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment |
![]() |
Human immunodeficiency virus |
![]() ![]() ![]() ![]() |
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection |
![]() |
Improved assays to measure and characterize the inducible HIV reservoir |
![]() |
International AIDS Society global scientific strategy: towards an HIV cure 2016. |
![]() |
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation |
![]() |
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections |
![]() |
A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. |
![]() |
A new perspective on V3 phenotype prediction. |
![]() |
A Plea for Justice for Jailed Medical Workers |
![]() |
Pleocytosis is associated with disruption of HIV compartmentalization between blood and cerebral spinal fluid viral populations |
![]() |
Public health. A sound rationale needed for phase III HIV-1 vaccine trials |
![]() |
Quantification of Total and 2-LTR (Long terminal repeat) HIV DNA, HIV RNA and Herpesvirus DNA in PBMCs |
![]() |
Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR |
![]() |
Recommendations for measuring HIV reservoir size in cure-directed clinical trials |
![]() |
Replicate Aptima assay for quantifying residual plasma viremia in individuals on ART |
![]() |
Replication competence of virions induced from CD4+ lymphocytes latently infected with HIV |
![]() |
Select host restriction factors are associated with HIV persistence during antiretroviral therapy |
![]() |
Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance |
![]() |
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection |
![]() |
Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study |
![]() |